logo    Company Page

Changed Risks for IRONWOOD PHARMACEUTICALS INC (IRWD)

Here are risks that changed year over year. risks from the recent filings of IRONWOOD PHARMACEUTICALS INC. Our algorithms work hard to highlight risks unique to this company.
Our business could be negatively affected as a result of a proxy contest or certain other stockholder actions
Item 3
If we identify a material weakness in our internal control over financial reporting, it could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock
We rely entirely on contract manufacturers, our partners and other third parties to manufacture and distribute linaclotide If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties, or are otherwise unable to manufacture and distribute sufficient quantities to meet demand, our commercialization efforts may be materially harmed  
We expect that the price of our common stock will fluctuate substantially
Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could negatively impact the market price of our common stock
The transition of lesinurad to AstraZeneca has been and continues to be a significant undertaking that could require additional substantial financial and managerial resources, and we may not be successful 
Ironwood continues to assess the US federal income tax consequences of potential structures to separate our business into two independent, publicly traded companies  If the separation is not generally tax-free for US federal income tax purposes, we and our stockholders could be subject to significant tax liabilities
Even though linaclotide is approved for marketing in the US and in a number of other countries, we or our partners may never receive approval to commercialize linaclotide in additional parts of the world
Even though LINZESS is approved by the FDA, it faces post-approval development and regulatory requirements, which present additional challenges 
In addition to the other information in this Annual Report on Form 10-K, any of the factors described below could significantly and negatively affect our business, financial condition, results of operations or prospects The trading price of our common stock may decline due to these risks
We have received notices of Paragraph IV certifications related to linaclotide in conjunction with ANDAs filed by generic drug manufacturers, and we may receive additional notices from others in the future  We have, and may continue to, become involved in legal proceedings to protect or enforce intellectual property rights relating to our products and our product candidates, which could be expensive and time consuming, and unfavorable outcomes in such proceedings could have a material adverse effect on our business
Convertible note hedge and warrant transactions entered into in connection with our 2022 Notes may affect the value of our common stock
The planned separation may not achieve some or all of the anticipated benefits
The planned separation of our business into two independent, publicly traded companies is subject to various risks and uncertainties and may not be completed on the terms or timeline currently contemplated, if at all, and will involve significant time, effort and expense, which could harm our business, results of operations and financial condition
Our products may cause undesirable side effects or have other properties that could limit their commercial potential 
We are highly dependent on the commercial success of LINZESS in the US for the foreseeable future; we cannot guarantee when, or if, we will attain profitability or positive cash flows
Legal Proceedings

Debug Info- Version: 2.6